Genomic Health Announces Presentation of Three Oncotype DX® Studies at the 8th European Breast Cancer Conference

Geneva (ots/PRNewswire) -

Results Reconfirm Test's Cost-Effectiveness, Emphasise Important
Role in Guiding Treatment Decisions

Genomic Health, Inc. today announced results of three new
Oncotype DX(R) studies including data demonstrating the test's
cost-effectiveness within the German and Hungarian healthcare
systems, and Israeli data showing the test's impact on treatment
decisions in early-stage invasive breast cancer patients with
lymph-node positive status. These findings will be presented during
poster sessions at the 8th European Breast Cancer Conference (EBCC)
in Vienna, Austria, March 21-24.

"We now have eight clinical studies involving more than 5,000
patients across Europe, showing the value the Oncotype DX test brings
to patients, physicians and payors," said Christer Svedman, director,
medical affairs in Europe, Genomic Health. "As international use of
the Oncotype DX breast cancer test increases, it's important to not
only have strong clinical data but also to demonstrate that using the
test is cost effective in different healthcare systems."

The Oncotype DX breast cancer test has been shown to predict the
likelihood of chemotherapy benefit as well as recurrence in
early-stage breast cancer. Multiple studies conducted in Germany,
Spain, the United Kingdom, Israel, Japan, Australia, and the United
States have shown the use of the test to change treatment decisions
in approximately 30 percent of patients. Additionally, nine health
economic analyses have consistently demonstrated the cost
effectiveness of Oncotype DX in the assessed healthcare systems in
Europe, Asia, Israel and North America.

Health Economics Analyses in Germany and Hungary Demonstrate
Oncotype DX's Cost Effectiveness

"As physicians, we are challenged to provide quality patient care
while exercising economic sense. Oncotype DX is a unique tool we can
use to help guide treatment recommendations for early-stage breast
cancer patients in a cost effective manner," said Wolfgang Eiermann,
M.D., professor of gynecology, Interdisciplinary Oncology Center,
Munich, Germany. "Oncotype DX is already included in international
clinical guidelines such as ESMO, St. Gallen, ASCO and NCCN[1] and
our research demonstrates that Oncotype DX is cost effective and
impacts treatment decisions ensuring that the right patients benefit
from chemotherapy, while others are spared unnecessary treatment and
associated toxicities."

- The results of a large prospective German multicenter study involving 366
patients have shown that use of the Oncotype DX changed initial recommendations in 33
percent of cases and demonstrate that using the test would be associated with an
increased survival and be cost effective in Germany. "Using the 21-gene breast cancer
assay in adjuvant decision-making in ER-positive (ER+) early breast cancer (EBC) is
cost-effective: Results of a large prospective German multicenter study" (Abstract
#302) will be presented on Friday, March 23.

- Additionally, a health economics analysis from Hungary finds the Oncotype
DX compares favourably with other oncology related health technologies being utilised
in the country and that using the Oncotype DX assay is likely to be cost effective in
Hungary. "The impact of chemotherapeutic regimens on the cost-utility analysis of
Oncotype DX assay" (Abstract #347) will be presented on Thursday, March 22.

Using Oncotype DX in Lymph Node-Positive Patients in Israel is
Likely to Reduce Use of Chemotherapy

- In an evaluation of the relationship between the Recurrence Score(R)
results and treatment decisions in patients with oestrogen receptor-positive,
node-positive, breast cancer in Israel, researchers found that patients who had the
Oncotype DX test were less likely to be recommended chemotherapy compared to patients
who did not have the test even when adjusting for variables such as grade and nodal
status (p<0.001). The study included 282 patients who received the Recurrence Score
and 669 control patients who did not receive the test. "Recurrence Score (RS) and
treatment decisions in node-positive (N+), oestrogen receptor-positive (ER+) breast
cancer patients in Israel" (Abstract #433) will be presented on Friday, March 23.

About Genomic Health

Genomic Health
[http://www.genomichealth.com/en-US/Company/LabVideo.aspx ], Inc. is
a global cancer company focused on the development and
commercialisation of genomic-based clinical laboratory services that
analyse the underlying biology of cancer allowing physicians and
patients to make individualised treatment decisions. Its lead
product, the Oncotype DX(R) breast cancer test, has been shown to
predict the likelihood of chemotherapy benefit [http://www.mybreastc
ancertreatment.org/en-US/MyBreastCancerTreatment/IsRightForMe.aspx ]
as well as recurrence in invasive breast cancer [http://www.mybreast
cancertreatment.org/en-US/UnderstandingBreastCancer/BreastCancerBasic
s.aspx ] and has been shown to the predict the likelihood of
recurrence in ductal carcinoma in situ (DCIS). In addition to this
widely adopted test, Genomic Health provides the Oncotype DX colon
cancer test, the first multigene expression test developed for the
assessment of risk of recurrence in patients with stage II disease.
As of December 31, 2011, more than 10,000 physicians in over 65
countries had ordered more than 265,000 Oncotype DX tests. Genomic
Health has a robust pipeline focused on developing tests to optimise
the treatment of prostate and renal cell cancers, as well as
additional treatment decisions in breast and colon cancers. In
February, the company announced plans to form a new wholly owned
genetics subsidiary to focus on the commercial applications of the
human genome, with the goal of making commercial services available
to physicians and patients in 2013. The company is based in Redwood
City, California with European headquarters in Geneva, Switzerland.
For more information, please visit, http://www.GenomicHealth.com. To
learn more about Oncotype DX tests, visit: http://www.OncotypeDX.com
and http://www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements relating to; the cost effectiveness of Oncotype
DXwithin the German and Hungarian healthcare systems; the ability of
the company's tests to optimise cancer treatment and impact clinical
practice; value the company's tests are delivering to physicians,
payers and patients; the applicability of cost effectiveness study
results to actual outcomes; the impact of clinical and cost
effectiveness studies on the use of the company's tests; the ability
of the company to successfully market its products outside of the US;
the ability of the company to develop additional tests in the future;
the scope, success or results of clinical trials and the timing of
such activities; and, the ability of the company's tests to be
adequately reimbursed. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risks and uncertainties
include, but are not limited to: the results of clinical and cost
effectiveness studies; the applicability of clinical study results to
actual outcomes; the risks and uncertainties associated with the
regulation of the company's tests by the FDA or similar agencies
around the world; our ability to develop and commercialise new tests;
unanticipated costs or delays in research and development efforts;
our ability to obtain and maintain reimbursement coverage for our
tests and the other risks set forth in the company's filings with the
Securities and Exchange Commission, including the risks set forth in
the company's Annual Report on Form 10-K for the period ended
December 31, 2011. These forward-looking statements speak only as of
the date hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.

[1]ESMO, ASCO and NCCN are registered trademarks of the European
Society of Medical Oncology, the American Society of Clinical
Oncology and National Comprehensive Cancer Network, respectively.
ESMO, St Gallen, ASCO and NCCN do not endorse any product or therapy.

http://www.genomichealth.com

ots Originaltext: Genomic Health, Inc.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Investors: Dean Schorno, Genomic Health,
+1-650-569-2281, investors@genomichealth.com ; Media: Victoria
Steiner,
Genomic Health, +1-415-370-5804, media@genomichealth.com